Joseph G. Pressey · Malignant peripheral nerve sheath tumor development during MEK inhibitor treatment: A pre-clinical study and a clinical case series.
Follow
Article1 min read·Published Nov 2026

Malignant peripheral nerve sheath tumor development during MEK inhibitor treatment: A pre-clinical study and a clinical case series.

pubmed.ncbi.nlm.nih.gov shows its articles on its own site.

Read the article on pubmed.ncbi.nlm.nih.gov ↗

Article · Nov 2026 · 1 min read

In brief

In brief

This study investigates the paradoxical development of malignant peripheral nerve sheath tumors in NF1 patients during MEK inhibitor therapy with selumetinib. Combining preclinical models with clinical case series, the research examines potential mechanisms of treatment-emergent malignant transformation in this high-risk population.

Written by the GCMD Library team from the article.

Joseph G. Pressey

People with Neurofibromatosis type 1 (NF1) are at risk of developing benign and malignant peripheral nerve sheath tumors (MPNST). In NF1, the overall lifetime risk of MPNST is estimated at 8%-13%, with increased risk associated with specific germline mutations and larger benign tumor burden. Selumetinib, a mitogen-activating protein kinase kinase inhibitor (MEKi), was the first FDA-approved therap…

Statements in this article

  1. People with Neurofibromatosis type 1 are at risk of developing benign and malignant peripheral nerve sheath tumors.

    Established
  2. In NF1, the overall lifetime risk of MPNST is estimated at 8%-13%.

    Established
  3. Increased MPNST risk is associated with specific germline mutations and larger benign tumor burden in NF1.

    Established
  4. Selumetinib, a mitogen-activating protein kinase kinase inhibitor, was the first FDA-approved therapy for NF1.

    Established

Read it at the source ↗

Try
Intelligent Search· scoped to this article · not medical adviceSearch the whole library →
GCMD Library — educational content from recorded physician discussions, not medical advice.